Similar articles

• Use of monoclonal antibodies in solid tumors diagnosis: the endometrial carcinoma.

  Bartolazzi A, Mottolese M, Vocaturo A, Vocaturo G, Bigotti A, Prat M, Atlante G, Natali PG. Bartolazzi A, et al. Cytotechnology. 1991;5 Suppl 1:35-40. Cytotechnology. 1991. PMID: 1367118 No abstract available.
• Bcl-2 expression and prognosis of patients with endometrial carcinoma.

  Sakuragi N, Ohkouchi T, Hareyama H, Ikeda K, Watari H, Fujimoto T, Kuwabara M, Yamamoto R, Sagawa T, Fujino T, Fujimoto S. Sakuragi N, et al. Int J Cancer. 1998 Apr 17;79(2):153-8. doi: 10.1002/(sici)1097-0215(19980417)79:2<153::aid-ijc10>3.0.co;2-b. Int J Cancer. 1998. PMID: 9583730
• Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody.

  Arai Y, Nishida M. Arai Y, et al. Int J Gynecol Cancer. 2003 Jan-Feb;13(1):42-6. doi: 10.1046/j.1525-1438.2003.13009.x. Int J Gynecol Cancer. 2003. PMID: 12631219
• Immunocytodiagnosis of solid tumors employing panels of monoclonal antibodies.

  Mottolese M, Venturo I, Salzano M, Benevolo M, Bigotti A, Natali PG. Mottolese M, et al. J Clin Lab Anal. 1993;7(4):238-42. doi: 10.1002/jcla.1860070409. J Clin Lab Anal. 1993. PMID: 8360799 Review. No abstract available.
• Monoclonal antibody treatment of solid tumors: a coming of age.

  Murray JL. Murray JL. Semin Oncol. 2000 Dec;27(6 Suppl 11):64-70; discussion 92-100. Semin Oncol. 2000. PMID: 11236030 Review.